OncLive TV

OncLive® TV is an editorial video program featuring one-on-one live and/or virtual interviews with key opinion leaders in the oncology field for their expert insight on breaking news, regulatory updates, practice-changing data presented at medical meetings, and other pivotal topics in a cancer specialty, including breast cancer, lung cancer, genitourinary cancers, gastrointestinal cancers, gynecologic cancers, and hematologic cancers.

Dr. Agarwal on Frontline Treatment in Kidney Cancer

July 18th 2018

Neeraj Agarwal, MD, associate professor, Division of Oncology, Department of Medicine, University of Utah School of Medicine, Huntsman Cancer Institute, discusses his preferred frontline treatment for patients with kidney cancer.

Dr. Hashmi on Immunotherapy in Prostate Cancer

July 18th 2018

Mehmood Hashmi, MD, assistant professor of medicine, University of Kansas Medical Center, discusses the use of immunotherapy in the treatment of patients with prostate cancer.

Dr. Kambhampati on the Impact of Next-Generation Sequencing in AML

July 18th 2018

Suman Kambhampati, MD, co-medical director, Blood Cancer Program, Sarah Cannon Research Institute, discusses the impact of next-generation sequencing (NGS) in acute myeloid leukemia (AML).

Dr. Tolaney on Abemaciclib Plus Pembrolizumab for HR+, HER2- Breast Cancer

July 18th 2018

Sara M. Tolaney, MD, MPH, instructor of medicine, Harvard Medical School, attending physician of medical oncology, Dana-Farber Cancer Institute, discusses the phase Ib results of abemaciclib (Verzenio) plus pembrolizumab (Keytruda) for hormone receptor-positive, HER2-negative metastatic breast cancer.

Dr. Hardesty on Second-Line Maintenance Therapy for Ovarian Cancer

July 17th 2018

Melissa Hardesty, MD, gynecologic oncologist, Alaska Women’s Cancer Center, discusses second-line maintenance therapy after frontline chemotherapy for patients with ovarian cancer.

Dr. Konecny on Resistance to PARP Inhibitors in Ovarian Cancer

July 17th 2018

Gottfried E. Konecny, MD, associate professor of medicine, University of California, Los Angeles, discusses resistance to PARP inhibitors in ovarian cancer.

Dr. Flinn on the RELEVANCE Trial in Follicular Lymphoma

July 17th 2018

Ian Flinn, MD, PhD, director of the Blood Cancer Research Program, Sarah Cannon Research Institute, discusses the RELEVANCE trial in follicular lymphoma.

Dr. Barr on Temozolomide and Capecitabine in Neuroendocrine Tumors

July 17th 2018

Jodie Barr, DO, hematologist/oncologist, Lawrence Memorial Hospital, discusses the combination of temozolomide and capecitabine in neuroendocrine tumors (NETs).

Dr. West Discusses Latest Immunotherapy Findings in Lung Cancer

July 17th 2018

H. Jack West, MD, medical director of thoracic oncology, Swedish Cancer Institute of Swedish Medical Center, discusses the latest immunotherapy findings for lung cancer treatment.

Dr. Yezefski Compares Costs and Outcomes of Chemotherapy in the US and Canada

July 16th 2018

Todd A. Yezefski, MD, senior fellow, Fred Hutchinson Cancer Research Center, University of Washington, compares the costs and outcomes of chemotherapy in the United States and Canada for patients with colorectal cancer.

Dr. Gomella on the FDA Approval of Enzalutamide in Nonmetastatic CRPC

July 13th 2018

Leonard Gomella, MD, professor, chair, Department of Urology, director, Sidney Kimmel Cancer Center Network, Thomas Jefferson University Hospital, discusses the FDA approval of enzalutamide (Xtandi) for the treatment of men with nonmetastatic castration-resistant prostate cancer.

Dr. Biran Discusses Treatment Discontinuation in Myeloma

July 13th 2018

Noa Biran, MD, physician, Multiple Myeloma Division, John Theurer Cancer Center, discusses treatment discontinuation in multiple myeloma.

Dr. Kolberg Provides a Global Perspective on Biosimilar Integration

July 13th 2018

Hans-Christian Kolberg, MD, head, Department of Obstetrics and Gynecology, Breast Cancer Center, and Gynecologic Cancer Center at Marienhospital Bottrop, Klinik für Gynäkologie und Geburtshilfe, provides a global perspective on the integration of biosimilars into cancer care.

Dr. Hilal Discusses Study of Rituximab Maintenance in MCL

July 13th 2018

Talal Hilal, MB, BCh, assistant professor of medicine, Mayo Clinic, discusses a study of rituximab (Rituxan) maintenance in patients with mantle cell lymphoma (MCL) after induction chemoimmunotherapy.

Dr. Hashmi on Imaging Modalities in Prostate Cancer

July 13th 2018

Mehmood Hashmi, MD, assistant professor of medicine, University of Kansas Medical Center, discusses imaging modalities in prostate cancer.

Dr. Talley on Clinical Trials for Patients With Chronic Leukemias

July 13th 2018

Robert L. Talley, MD, hematologist/medical oncologist, Centerpoint Medical Center, Sarah Cannon Cancer Institute, discusses clinical trials for patients with chronic leukemias.

Dr. Bailey on Clinical Needs in Pediatric Patients With Bone Sarcoma

July 13th 2018

Kelly Bailey, MD, PhD, physician, department of Pediatric Hematology/Oncology, Children's Hospital of Pittsburgh, University of Pittsburgh Medical Center, discusses clinical needs in pediatric patients with bone sarcoma.

Dr. Kambhampati on BCL-2 Inhibition in Acute Myeloid Leukemia

July 13th 2018

Suman Kambhampati, MD, co-medical director, Blood Cancer Program, Sarah Cannon Research Institute, discusses BCL-2 inhibition in acute myeloid leukemia (AML).

Dr. Van Veldhuizen on the Combination of Atezolizumab and Bevacizumab in Kidney Cancer

July 13th 2018

Peter J. Van Veldhuizen, MD, hematologist/oncologist, Sarah Cannon Research Institute, discusses the frontline combination of atezolizumab (Tecentriq) and bevacizumab (Avastin) in the treatment of patients with kidney cancer.

Dr. Ellis on Resistance to Endocrine Therapy in HR+ Metastatic Breast Cancer

July 13th 2018

Matthew J. Ellis, MD, PhD, professor and director, Lester and Sue Smith Breast Center, associate director of precision medicine, Dan L. Duncan Comprehensive Cancer Center, Baylor College of Medicine, discusses resistance to endocrine therapy in hormone receptor (HR)-positive breast cancer.